Select Language:
The Yangtze River Delta, the Beijing-Tianjin-Hebei region, and the Guangdong-Hong Kong-Macao Greater Bay Area are China’s most economically developed urban clusters, hosting 90% of the country’s pre-unicorn startups, according to a recent report.
Among the 100 pre-unicorn companies nationwide, 59 are based in the Yangtze River Delta, 17 in the Beijing-Tianjin-Hebei area, and 14 in the Greater Bay Area. A report from the China Center for Information Industry Development Technology Innovation highlights these distribution patterns.
Pre-unicorns are innovative, fast-growing tech firms valued at less than $1 billion but demonstrating significant potential for rapid expansion. They are expected to become unicorns—privately held startups valued at over $1 billion—within three to five years, often established within the past decade.
A total of 24 Chinese cities are home to at least one pre-unicorn company. Shanghai leads with 18 companies, followed by Beijing with 17. Other notable cities include Suzhou with eight, Shenzhen with seven, and Guangzhou and Nanjing with six each.
The list of companies spans sectors such as integrated circuits, biotechnology, autonomous vehicle technology, renewable energy, artificial intelligence, robotics, and commercial aerospace. Of these, 36 are concentrated in the IC market, valued collectively at nearly $24.9 billion. Another 14 companies involved in biomanufacturing have a combined valuation close to $9.9 billion.
Shanghai boasts a comprehensive supply chain ecosystem that covers chip design, manufacturing, and high-end equipment. Its status as a major financial hub offers long-term advantages supporting technology-intensive, long-cycle chip startups.
Suzhou benefits from its ability to quickly handle tape-out, packaging, testing, and system integration for chips designed in Shanghai, thanks to its established IC packaging, testing, and manufacturing facilities.
Additionally, Shanghai has developed the densest and most complete biopharmaceutical industrial cluster in China. It encompasses the entire supply chain—from target discovery and compound screening to preclinical trials, clinical research, and large-scale production—providing strong support for the fast-paced growth of biotech pre-unicorn companies.
ChatGPT
Perplexity
Gemini AI
Grok AI
